Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis
-
Published:2024-05
Issue:
Volume:
Page:
-
ISSN:0016-5085
-
Container-title:Gastroenterology
-
language:en
-
Short-container-title:Gastroenterology
Author:
Leonhardt Carl-StephanORCID,
Gustorff Charlotte,
Klaiber Ulla,
Le Blanc Solange,
Stamm Tanja A.,
Verbeke Caroline S.,
Prager Gerald W.,
Strobel Oliver
Reference88 articles.
1. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017;Lancet Gastroenterol Hepatol,2019
2. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet,2017
3. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer;Conroy;N Engl J Med,2018
4. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma;Groot;Ann Surg,2019
5. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma;Groot;Ann Surg,2018